Amryt Pharma plc (AMYT) - Financial and Strategic SWOT Analysis Review

  • ID: 4285046
  • SWOT Analysis
  • 25 pages
  • GlobalData
  • Amryt Pharma plc
1 of 5

Amryt Pharma plc (Amryt), formerly Fastnet Equity plc is a specialty pharmaceutical company that develops, manufactures and commercializes novel treatments for patients with rare and orphan diseases. The company’s lead product, Episalvan (betulin), is approved in Europe for the treatment of partial-thickness wounds (PTWs) in adults; and another product, Imlan (betulin), is a skin care line that improves dry, itching and allergic skin. The company is also developing a portfolio of pipeline candidates, namely, Episalvan (AP101) and AP102 targeting multiple orphan diseases such as epidermolysis bullosa, acromegaly and Cushing’s disease. The company operates through offices in Germany and Ireland. Amryt is headquartered in London, the UK.

Amryt Pharma plc Key Recent Developments

Jan 24, 2018: Amryt Pharma: Senior Management Team Appointment
Dec 20, 2017: Amryt Pharma: Senior Management Team Appointment
Sep 04, 2017: Amryt Pharma: Interim results for the six months ended 30 June 2017
Aug 30, 2017: Amryt Pharma Announce the Appoints of Kieran Rooney
Aug 30, 2017: Amryt Appoints Kieran Rooney, Ph.D., as Vice President of Strategic Alliances and Licensing

This comprehensive SWOT profile of Amryt Pharma plc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of the author’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, the author’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Amryt Pharma plc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
*Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Product cover images may vary from those shown
2 of 5
Section 1 - About the Company
  • Amryt Pharma plc - Key Information
  • Amryt Pharma plc - Overview
  • Amryt Pharma plc - Key Employees
  • Amryt Pharma plc - Key Employee Biographies
  • Amryt Pharma plc - Key Operational Heads
  • Amryt Pharma plc - Major Products and Services
  • Amryt Pharma plc - History
  • Amryt Pharma plc - Company Statement
  • Amryt Pharma plc - Locations And Subsidiaries
  • Amryt Pharma plc - Key Manufacturing facilities
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Amryt Pharma plc - Business Description
  • Amryt Pharma plc - Corporate Strategy
  • Amryt Pharma plc - SWOT Analysis
  • SWOT Analysis - Overview
  • Amryt Pharma plc - Strengths
  • Amryt Pharma plc - Weaknesses
  • Amryt Pharma plc - Opportunities
  • Amryt Pharma plc - Threats
  • Amryt Pharma plc - Key Competitors
Section 3 - Company Financial Performance Charts
  • Amryt Pharma plc - Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Appendix
  • Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
*Note: Some sections may be missing if data is unavailable for the company

List of Tables
  • Amryt Pharma plc, Key Information
  • Amryt Pharma plc, Key Ratios
  • Amryt Pharma plc, Share Data
  • Amryt Pharma plc, Major Products and Services
  • Amryt Pharma plc, History
  • Amryt Pharma plc, Key Employees
  • Amryt Pharma plc, Key Employee Biographies
  • Amryt Pharma plc, Key Operational Heads
  • Amryt Pharma plc, Other Locations
  • Amryt Pharma plc, Subsidiaries
  • Amryt Pharma plc, Key Manufacturing facilities
  • Amryt Pharma plc, Key Competitors
  • Amryt Pharma plc, SWOT Analysis
  • Amryt Pharma plc, Ratios based on current share price
  • Amryt Pharma plc, Annual Ratios
  • Amryt Pharma plc, Interim Ratios
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Amryt Pharma plc, Performance Chart
  • Amryt Pharma plc, Ratio Charts
Note: Product cover images may vary from those shown
3 of 5


4 of 5
  • NIHR Innovation Observatory
  • Biotechnology and Biological Sciences Research Council
  • Alder Hey Children's NHS Foundation Trust
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown